Opus Genetics, Inc. (IRD)
Nasdaq · Healthcare · Biotechnology
$4.38−4.37%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $364M
- 52-week range
- $1.70 – $7.07
- 52-week change
- +126.73%
- EPS (trailing)
- −$1.22
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $14.2M (+29.15%)
- Net income
- −$49.6M
- Operating margin
- −271.9%
- Diluted EPS
- −$0.80
From the company’s annual report on SEC EDGAR.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.
Headquarters: Durham, United States · 27 employees · opusgtx.com